Solar stocks tumbled after Senate Republicans maintained a full phase-out of [solar and wind-energy tax credits]( ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Shares of Verve Therapeutics ( VERV 76.56%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly ( LLY -0.90%) and Verve Therapeutics announced a "definitive ...

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Shares of Verve Therapeutics skyrocketed 75% in premarket trading Tuesday after Eli Lilly announced it would acquire the gene-editing startup for about $1.3 billion.

Novo Nordisk, the maker of Ozempic and Wegovy, is predicted to lose billions in profits due to a minor billing error in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...